Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugspriority health Part B Prior Auth & Coverage | Ope…
    Ask Trek AI about this page
    Currentpriority healthPolicy N/A

    Priority Health Medicare Part B prior authorization and step therapy criteria for Part B drugs

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs prior authorization (PA) and step therapy (ST) requirements for Medicare Part B outpatient drugs and biologics administered by providers, and guides providers on use of the Medical Drug List (MDL) and Medicare coverage resources.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Part B prior authorization and step therapy criteria for Part B drugs
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionComplete the Medicare Part B drug request form or Web Form and submit supporting medical records including prior therapies and responses to request prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-07-01last revised
    Yesstep therapy applied
    <10%ADAMTS13 requirement
    1–2y

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    typical coverage duration
    Severalbiosimilar interchangeability noted

    Coverage Criteria by Product

    Actemra IV — Covered with criteria

    Actemra IV (tocilizumab) coverage and restrictions

    Actemra IV coverage and restrictions: Covered for all medically accepted indications not otherwise excluded; dose approved per FDA labeling or accepted standards; coverage duration 2 years; prescriber must be a specialist or have consulted a specialist; required medical records must document prior therapies and responses; patient must first try Tyenne prior to approval.

    Exclusions: must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; SSc-ILD not approved for IV administration.

    Adakveo (crizanlizumab) Initial Therapy

    Covered when ALL of the following are met

    Adakveo initial coverage: 1) Request submitted via the Medicare Part B (Non-Oncology) drug request form or Web Form; 2) Medical records supporting the request provided; 3) Patient has tried hydroxyurea for 6 months or has documented intolerance/contraindication to hydroxyurea; 4) Dose per FDA labeling or accepted standards of practice; 5) Coverage duration: 2 years.

    Adakveo is a Priority Health Part B Step Therapy Drug; 6-month hydroxyurea trial recommended per evidence/guidance.

    Adzynma (rADAMTS13) Initial Therapy

    Covered when ALL of the following are met

    Adzynma initial coverage: 1) Request submitted via the Medicare Part B drug request form or Web Form; 2) Genetic testing confirming diagnosis of congenital TTP (cTTP); 3) ADAMTS13 activity < 10%; 4) Medical records provided including current weight for dosing; 5) Initial dosing every 2 weeks (may be adjusted to weekly based on prior regimen or clinical response with supporting documentation); 6) Coverage duration: initial 12 months.ADAMTS13 <10%

    Reauthorization requires demonstration of benefit (see reauthorization criteria).

    Alhemo (hemophilia prophylaxis) Initial and Continuation

    Covered when ALL of the following are met

    Alhemo initial coverage: 1) Request submitted via the Medicare Part B drug request form or Web Form; 2) Medical records supporting routine prophylaxis for hemophilia A or B provided; 3) For hemophilia A: documentation that patient has tried and failed Hemlibra; 4) Prescribed by or in consultation with a hematologist or other specialist; 5) Patient is at least 12 years of age for Alhemo Pen; 6) Coverage duration: initial 12 months.

    Dose per FDA labeling or accepted standards of medical practice; reauthorization requires documentation of clinical benefit.

    Alhemo Reauthorization

    Reauthorization criteria for Alhemo

    Alhemo reauthorization: 1) Patient continues to use Alhemo for routine prophylaxis to prevent or reduce bleeding episodes; AND 2) Documentation of clinical benefit (e.g., fewer bleeding episodes, decreased use of factor VIII/IX replacement therapy or bypassing agents) has been provided.

    Reauthorization duration: 12 months.

    Alyglo Coverage

    Coverage requirements for Alyglo

    Alyglo initial approval: 1) Request submitted via the Medicare Part B (Non-Oncology) drug request form or Web Form; 2) Medical records supporting the request provided, including documentation of prior therapies and responses; 3) Dose per FDA labeling or accepted standards of medical practice; 4) Coverage duration: 2 years.

    Part B vs Part D determination required.

    Alyglo step therapy: If determined to be a Part B benefit, patient must first try two preferred IVIG products (e.g., Gammagard Liquid, Gamunex-C, Privigen) prior to approval.

    Refer to LCD L34771 for IVIG requirements.

    Alymsys Coverage

    Coverage requirements for Alymsys (bevacizumab-maly)

    Alymsys initial approval: 1) Request submitted via the Medicare Part B Oncology (Cancer Therapy) drug request form or Web Form; 2) Medical records supporting the request provided, including documentation of prior therapies and responses; 3) Dose per FDA labeling or accepted standards of medical practice; 4) Coverage duration: up to 1 year.

    Criteria applied consistent with LCD L37205.

    Alymsys step therapy: Patient must first try Mvasi AND Zirabev prior to coverage of Alymsys.

    Per policy and NCCN support for biosimilars as substitutes.

    Initial Therapy Criteria — generic grouping for initial authorization language

    Covered when ALL of the following are met for the specified indication

    Indication branch

    • Initial hATTR-PN: 1) Patient has a pathogenic transthyretin (TTR) mutation; 2) Baseline Polyneuropathy Disability (PND) score ≤ IIIb; 3) Clinical signs/symptoms of polyneuropathy (e.g., motor disability, peripheral/autonomic neuropathy); 4) Age ≥ 18 years.

      Required medical records must be provided.

    • Initial ATTR-CM: 1) NYHA class I–III heart failure with current manifestations or prior HF hospitalization; 2) ECHO or CMR demonstrating increased LV wall thickness; 3) Diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTcPYP/DPD/HMDP); 4) If radionuclide imaging used, documentation of Grade 2 or 3 cardiac uptake; 5) Must try and fail tafamidis (Vyndamax or Vyndaqel); 6) Age ≥ 18 years.

      Required medical records must be provided.

    Reauthorization Criteria — generic grouping for continuation language

    Reauthorization covered when ALL of the following are met

    Reauthorization: Documentation demonstrating positive clinical response compared to baseline is provided (hATTR-PN: improved neuropathy symptoms, motor function, quality of life, or slowed progression; ATTR-CM: reduced cardiovascular-related hospitalizations, improved function, or improved quality of life).

    Coverage duration: 1 year for reauthorization.

    Asceniv - Initial Therapy

    Asceniv (IVIG) - Covered when ALL of the following are met

    Asceniv initial coverage: 1) Request submitted via Medicare Part B (Non-Oncology) drug request form or Web Form; 2) Medical records supporting the request provided, including documentation of prior therapies and responses; 3) For requests determined to be a Part B benefit, patient must have tried two preferred IVIG products (e.g., Gammagard Liquid, Gamunex-C, Privigen); 4) Coverage duration: 2 years; 5) Dose per FDA labeling or accepted standards of practice.

    Refer to LCD L34771 as applicable.

    Aukelso - Initial Therapy

    Aukelso (denosumab biosimilar) - Covered when ALL of the following are met

    Aukelso initial coverage: 1) Request submitted via Medicare Part B (Non-Oncology) drug request form or Web Form; 2) Medical records supporting the request provided; 3) Patient must first try Wyost, Xtrenbo, AND Bilprevda prior to Aukelso; 4) Coverage duration: up to 2 years; 5) Dose per FDA labeling or accepted standards of practice.

    Aukelso is FDA-approved for the same indications as reference product and provisionally interchangeable with Xgeva.

    Avastin - Initial Therapy

    Avastin (bevacizumab — J9035 chemotherapy only) - Covered when ALL of the following are met

    Avastin initial coverage: 1) Request submitted via the Medicare Part B Oncology (Cancer Therapy) drug request form or Web Form; 2) Medical records supporting the request provided, including documentation of prior therapies and responses; 3) Patient must first try Mvasi AND Zirabev prior to Avastin (J9035); 4) Coverage duration: up to 1 year; 5) Dose per FDA labeling or accepted standards of practice.

    Criteria applied consistent with LCD L37205; J9035 billing applies.

    Aveed - Initial Therapy

    Aveed (testosterone undecanoate) - Covered when ALL of the following are met

    Aveed hypogonadism coverage: 1) Request submitted via Medicare Part B (Non-Oncology) drug request form or Web Form; 2) Medical records supporting the request provided; 3) Patient has tried and failed generic testosterone cypionate or enanthate AND a generic topical testosterone therapy; 4) Two pre-treatment morning serum total testosterone levels on separate days <300 ng/dL or low per laboratory reference; 5) Clinical signs/symptoms consistent with testosterone deficiency other than erectile dysfunction or decreased libido; 6) Patient was assigned male at birth; 7) Coverage duration: 2 years; 8) Dose per FDA labeling or accepted standards of practice.two morning serum total testosterone <300 ng/dL

    For gender dysphoria: prior trials of injectable and topical generic testosterone required and supporting documentation.

    Avgemsi: Coverage with step therapy

    Avgemsi coverage conditions:

    Avgemsi coverage criteria: Covered for medically accepted indications when medical records document prior therapies and responses; patient must first try generic gemcitabine injection prior to Avgemsi approval; coverage duration up to 1 year.

    Step therapy applies; Avgemsi not shown to offer efficacy/safety advantage over other gemcitabine formulations.

    Avopef: Coverage with step therapy

    Avopef coverage conditions:

    Avopef coverage criteria: Covered for medically accepted indications when medical records document prior therapies and responses; patient must first try generic etoposide prior to Avopef approval; coverage duration 1 year.

    Step therapy applies; approval based on evidence for generic etoposide.

    Avtozma: Coverage and exclusions

    Avtozma coverage conditions:

    Avtozma coverage criteria: 1) Request submitted via Medicare Part B drug request form or Web Form; 2) Medical records supporting the request provided, including documentation of prior therapies and responses; 3) Prescriber is a specialist or has consulted with a specialist; 4) Not used in combination with other biologic drugs, Otezla, or JAK inhibitors; 5) Dose per FDA labeling or accepted standards; 6) Coverage duration: up to 2 years.

    For most indications (except CRS, GCA, COVID-19) must first try Avsola OR Renflexis per step therapy guidance.

    Avtozma - Covered with criteria

    Covered when ALL of the following are met

    Avtozma coverage criteria: 1) Indication is a medically accepted indication for tocilizumab; 2) Prescriber is a specialist or has consulted a specialist; 3) Trial and failure of Avsola OR Renflexis for all medically accepted indications except cytokine release syndrome, giant cell arteritis, and certain COVID-19 scenarios; 4) Not used in combination with other biologic drugs, Otezla, or JAK inhibitors; 5) Required medical records documenting prior therapies and responses are provided; 6) Dose consistent with FDA labeling or accepted standards; 7) Coverage duration up to 2 years.

    NIH and specialty guidance apply for CRS and COVID-19 treatment contexts.

    Axtle - Covered with criteria

    Covered when ALL of the following are met

    Axtle coverage criteria: 1) Indication is a medically accepted indication for pemetrexed; 2) Medical records supporting the request provided including prior therapies and responses; 3) Patient must first try generic pemetrexed prior to Axtle approval; 4) Dose per FDA labeling or accepted standards; 5) Coverage duration up to 1 year.

    NCCN guidelines do not favor one pemetrexed product over another.

    Azmiro - Covered with criteria

    Covered when ALL of the following are met

    Azmiro indications

    • Azmiro hypogonadism criteria: 1) Trial and failure of generic testosterone cypionate; 2) Two pre-treatment morning serum total testosterone levels on separate days <300 ng/dL or below laboratory reference range; 3) Clinical signs/symptoms consistent with testosterone deficiency other than erectile dysfunction or decreased libido; 4) Patient was assigned male at birth; 5) Required medical records provided; 6) Dose per FDA labeling or accepted standards; 7) Coverage duration up to 2 years.two morning serum total testosterone <300 ng/dL

      Failure defined as inability to improve symptoms or testosterone levels.

    • Azmiro gender dysphoria criteria: 1) Documentation supporting need for gender-affirming hormone therapy; 2) Trial and failure of generic testosterone cypionate and a generic topical testosterone therapy where applicable; 3) Required medical records provided; 4) Dose per FDA labeling or accepted standards; 5) Coverage duration up to 2 years.

      Guidelines do not recommend one testosterone product over another.

    Beizray / Beizray kit Coverage

    Beizray (docetaxel) and Beizray kit covered when ALL of the following are met

    Beizray Initial Coverage: Covered for all medically accepted indications not otherwise excluded; medical records supporting the request must be provided; dose per FDA labeling or accepted standards of practice; coverage duration 1 year.
    Step therapy requirement: Must first try generic docetaxel (Taxotere, J9171) prior to Beizray approval.

    Benlysta (belimumab) Coverage

    Benlysta IV covered when ALL of the following are met (distinct criteria for SLE and lupus nephritis)

    Benlysta general: Covered for medically accepted indications not otherwise excluded; must not be used with another biologic drug or Lupkynis; prescriber must be a specialist or have consulted one; dose per FDA labeling; initial coverage 1 year; reauthorization 2 years.

    Medical records supporting the request required.

    SLE initial coverage: SELENA-SLEDAI score >= 6 AND either anti-dsDNA >30 IU/ml or ANA >1:80 AND patient has been taking standard of care that includes two of: a steroid, an immunosuppressant, hydroxychloroquine for at least 12 weeks each.SELENA-SLEDAI >= 6

    Medical records and disease-specific testing required.

    SLE reauthorization: Evidence of clinical improvement since starting Benlysta must be provided.

    Reauthorization duration 2 years.

    Bivigam coverage criteria

    Covered when ALL of the following are met for Part B requests:

    Bivigam (IVIG) initial: 1) Request submitted via Medicare Part B (Non-Oncology) drug request form or Web Form; 2) Medical records supporting the request provided, including documentation of prior therapies and responses; 3) For Part B determinations, patient must first try two preferred IVIG products (e.g., Gammagard Liquid, Gamunex-C, Privigen); 4) Coverage duration: 2 years; 5) Dose per FDA labeling or accepted standards of practice.

    Refer to LCD L34771 for IVIG guidance.

    Bkemv coverage criteria

    Covered when ALL of the following condition-specific criteria are met (examples shown):

    NMOSD initial: 1) Patient is AQP4 antibody positive; 2) Patient has tried and failed Epysqli (inadequate response or intolerance); 3) Bkemv will not be used in combination with Uplizna, Enspryng, or other NMOSD medications; 4) Medical records supporting the request provided; 5) Initial coverage duration 1 year.

    Reauthorization requires decreased relapse rate and supporting records.

    PNH initial: 1) Diagnosis confirmed by flow cytometry; 2) Presence of hemolysis-associated symptoms (e.g., thrombosis, organ dysfunction, pain); 3) Tried and failed Epysqli; 4) Bkemv will not be used in combination with other complement drug therapy; 5) Medical records supporting the request provided.flow cytometry confirmation

    Reauthorization requires clinical improvement and lab response.

    aHUS initial: 1) Shiga toxin-related HUS and TTP ruled out; 2) Tried and failed Epysqli; 3) Medical records supporting the request provided.

    Bkemv initial authorization

    Bkemv covered when ALL of the following are met:

    Bkemv initial authorization: 1) Baseline MG-ADL score >= 6; 2) Diagnosis of generalized myasthenia gravis that is AChR-Ab positive; 3) Tried and failed Epysqli (inadequate response or intolerance); 4) Tried Vyvgart or Vyvgart Hytrulo with intolerance or inadequate response; 5) Bkemv will not be used in combination with similar MG therapies; 6) Medical records supporting the request provided.MG-ADL >= 6

    Initial authorization duration 1 year.

    Bkemv reauthorization

    Bkemv reauthorization when ALL of the following are met:

    Bkemv reauthorization criteria: 1) Bkemv will not be used in combination with similar MG therapies (chronic immune globulin therapy, Vyvgart, Ultomiris, Rystiggo, Zilbrysq); 2) Documentation of improvement in MG-ADL total score from baseline has been provided; 3) Medical records supporting the request provided.improvement in MG-ADL

    Reauthorization duration 2 years.

    Bomyntra coverage

    Bomyntra coverage conditions:

    Bomyntra initial criteria: Covered for medically accepted indications not otherwise excluded; medical records supporting the request provided; patient must first try Wyost, Xtrenbo, AND Bilprevda; dose per FDA labeling or accepted standards; coverage duration up to 2 years.

    Step therapy applies.

    Boruzu coverage

    Boruzu coverage conditions:

    Boruzu initial criteria: Covered for medically accepted indications not otherwise excluded; medical records supporting the request provided; patient must first try one generic bortezomib injectable (e.g., HCPCS J9049 or J9041); dose per FDA labeling or accepted standards; coverage duration up to 1 year.

    Oncology step therapy applies.

    Bosaya coverage

    Bosaya coverage conditions:

    Bosaya initial criteria: Covered for medically accepted indications not otherwise excluded; medical records supporting the request provided; patient must first try Jubbonti, Enoby, AND Bildyos; dose per FDA labeling or accepted standards; coverage duration up to 2 years.

    Step therapy applies.

    Initial Therapy (Casgevy)

    Casgevy — Covered when ALL of the following are met

    Casgevy initial therapy criteria: 1) FDA-approved indication (Sickle Cell Disease or transfusion-dependent beta thalassemia) AND 2) Medical records supporting the request provided AND 3) For SCD: genetic confirmation of qualifying genotype (βS/βS, βS/β0, or βS/β+) AND history of ≥2 severe vaso-occlusive events per year in the previous 2 years; For beta thalassemia: transfusion dependence defined as ≥100 mL/kg/year or ≥10 units/year pRBC in prior 2 years AND no known/available HLA-matched donor and provider attestation patient would be eligible for HSCT in absence of matched donor AND 4) Current weight provided AND 5) Adequate organ function and eligibility for HSCT including ability to undergo myeloablative conditioning AND 6) No contraindication to required products or procedures for gene therapy.Patient ≥12 years for eligibility; authorization 6 months; limit 1 lifetime dose

    Prescriber must be or consult with a hematologist or appropriate provider.

    Initial Therapy (Cimzia)

    Cimzia — Covered when ALL of the following are met

    Cimzia initial therapy criteria: 1) Use for a medically accepted indication AND 2) Not used in combination with other biologic drugs, Otezla, or JAK inhibitors AND 3) Documentation that patient has tried and failed two listed alternative therapies (preferred adalimumab product, Rinvoq, Skyrizi, Tyenne, Cosentyx, Otezla, Xeljanz/Xeljanz XR, Yesintek/Selarsdi, or Enbrel) unless contraindicated or not tolerated AND 4) Prescriber is a specialist or has consulted with a specialist; coverage duration 2 years.

    Step therapy applies; medical records required.

    Cinqair Initial Therapy

    Cinqair — Covered when ALL of the following are met

    Cinqair initial coverage criteria: 1) Request submitted via Medicare Part B drug request form or Web Form with supporting medical records including documentation of prior therapies and responses; 2) Patient's current weight provided; 3) For severe eosinophilic asthma: blood eosinophils ≥150 cells/mcL at therapy start OR ≥300 cells/mcL in the prior 12 months; 4) Tried and failed 1 ICS/LABA plus 1 other asthma controller medication in the past 6 months (failure defined as intolerance or lack of improvement after at least 4 weeks); 5) Not used in combination with other biologic drugs; 6) Coverage duration: initial 2 years; reauthorization 2 years.eosinophil criteria: ≥150 cells/mcL at start OR ≥300 cells/mcL prior 12 months

    Medical records and weight required.

    Cinqair Reauthorization

    Cinqair reauthorization covered when ALL are met:

    Cinqair reauthorization: Documented clinical benefit such as decreased exacerbations, improved symptoms, or decreased oral steroid use has been provided.clinical improvement

    Reauthorization duration 2 years.

    Cinryze Initial Therapy

    Cinryze coverage conditions:

    Cinryze requirement: Medical records supporting the request provided including documentation of prior therapies and responses; patient must first try Haegarda prior to Cinryze approval; coverage duration 2 years; dose per FDA labeling or accepted standards.prior trial of Haegarda

    Conexxence Initial Therapy

    Conexxence coverage conditions:

    Conexxence requirement: Medical records supporting the request provided including documentation of prior therapies and responses; patient must first try Jubbonti, Enoby, AND Bildyos prior to Conexxence approval; coverage duration up to 2 years; dose per FDA labeling or accepted standards.prior trials of listed products

    Conexxence is a biosimilar to Prolia; interchangeable use noted.

    Cosentyx IV — Covered with Criteria

    Covered when ALL of the following are met

    Cosentyx IV coverage criteria: 1) Request submitted via Medicare Part B (Non-Oncology) drug request form or Web Form with supporting medical records including documentation of prior therapies and responses; 2) Prescriber is a specialist or has consulted with a specialist; 3) Prior trial of Avsola, Renflexis OR Simponi Aria required before Cosentyx IV approval; 4) Not used in combination with other biologic drugs, Otezla, or JAK inhibitors; 5) Coverage duration: 2 years; 6) Dose per FDA labeling or accepted standards.

    Cosentyx is indicated for PsO, PsA, RA, AS; step therapy applies.

    Docivyx — Covered with Criteria

    Covered when ALL of the following are met

    Docivyx coverage criteria: 1) Request submitted via Medicare Part B drug request form or Web Form with supporting medical records; 2) Patient must first try generic docetaxel (Taxotere, J9171) prior to Docivyx approval; 3) Coverage duration: 1 year; 4) Dose per FDA labeling or accepted standards.

    Docivyx is a polysorbate-80–free docetaxel formulation; no proven clinical advantage over generic docetaxel.

    Durysta — Covered with Criteria

    Covered when ALL of the following are met

    Durysta coverage criteria: 1) Request submitted via Medicare Part B drug request form or Web Form with supporting medical records including prior therapies and responses; 2) Patient must have tried TWO topical prostaglandin analogs (latanoprost, bimatoprost, travoprost) prior to Durysta; 3) Dose per FDA labeling or accepted standards; 4) Coverage duration per FDA labeling or accepted standards.

    Durysta indicated for open-angle glaucoma or ocular hypertension; step therapy applies.

    Entyvio Reauthorization

    Reauthorization requires:

    Entyvio reauthorization: Documented positive clinical response to Entyvio (examples: decrease in bowel movements per day, absence of blood in stool, decrease in oral steroid use, or decreased inflammatory markers such as fecal calprotectin or CRP) must be provided.

    Reauthorization duration: 2 years.

    Enjaymo Initial Therapy

    Covered when ALL of the following are met:

    Enjaymo initial criteria: 1) Confirmed diagnosis of cold agglutinin disease (CAD); 2) Documentation of at least one blood transfusion within 6 months prior to starting Enjaymo; 3) Presence of one or more symptoms associated with CAD (e.g., symptomatic anemia, acrocyanosis, Raynaud's phenomenon, hemoglobinuria, disabling circulatory symptoms, or a major adverse vascular event); 4) Documented trial and failure with a rituximab-containing regimen; 5) Patient is ≥18 years old and prescriber is a hematologist or consulted with a hematologist.>=1 transfusion within 6 months

    Initial coverage: 6 months; dosing per weight-based FDA regimen.

    Requests for biologic agents should follow the policy's combination-therapy exclusions: Actemra (tocilizumab) — including biosimilars such as Avtozma — must not be used in combination with other biologic drugs, Otezla (apremilast), or Janus Kinase inhibitors (JAKis). The policy notes these combinations increase infection and immunosuppression risk and are therefore excluded. Providers must also supply medical records documenting prior therapies and responses and follow stated step-therapy requirements (e.g., trying Tyenne before Actemra) when applicable.

    For certain products the policy explicitly lists no additional exclusion criteria ('Exclusion Criteria: N/A'). Examples in this document include Adakveo, Adzynma, and Alhemo where the policy records no product-specific exclusions beyond the general program rules; providers should still submit required medical records and meet the product-specific prior‑therapy and diagnostic requirements.

    Alyglo is listed with Exclusion Criteria: N/A in the policy. If the request is determined to be a Part B benefit, providers must still provide medical records documenting prior therapies and responses and satisfy any applicable Part B step‑therapy requirements (for example, trying two preferred IVIG products when required).

    Amvuttra must not be used in combination with TTR stabilizers (e.g., tafamidis) or TTR‑lowering agents (e.g., patisiran/Onpattro). The policy states Amvuttra will not be approved for primary (light‑chain) amyloidosis and notes there is insufficient evidence to support combination use with other TTR therapies.

    Several products in the document are shown with Exclusion Criteria: N/A in their coverage sections (examples include Asceniv, Aukelso, Avastin (J9035 chemotherapy only), and Aveed). Even when explicit exclusions are not listed, requests must include the required medical records and meet any step‑therapy or diagnostic prerequisites outlined for those products.

    Avtozma (a tocilizumab biosimilar) carries the same combination‑therapy exclusion as the reference product: it must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors. For most indications the policy also requires trial of Avsola OR Renflexis prior to Avtozma except where specific guidance (e.g., CRS, GCA, certain COVID scenarios) overrides the step‑therapy requirement.

    The policy explains that tocilizumab (and its biosimilars such as Avtozma) has not been studied in combination with other biologics, Otezla, or JAK inhibitors and that coadministration is unsupported; use in such combinations is therefore not recommended and may be excluded from coverage. In CRS management tocilizumab is typically given with glucocorticoids per standard practice, but other combinations lack supporting data.

    Benlysta (intravenous belimumab) must not be used concurrently with another biologic drug or with Lupkynis. The policy states Benlysta has not been studied in combination with other biologics or Lupkynis and combination use is unsupported; such use may lead to denial of coverage.

    The document emphasizes that there are no data supporting the combination of Benlysta with other biologic agents or Lupkynis; therefore concomitant use is not recommended and may be denied. For biosimilar complement inhibitors (Bkemv) the policy similarly restricts combination use with other complement therapies to avoid overlapping complement blockade and infection risk.

    Initial Therapy Criteria (Product-specific)

    inv-210: Actemra IV initial therapy

    Initial coverage requirements for Actemra IV

    Initial Actemra IV requirements: Must first try Tyenne; prescriber must be a specialist or have consulted a specialist; provide medical records documenting prior therapies and responses; dose per FDA labeling; coverage duration 2 years.

    Exclusions include combination with other biologics, Otezla, or JAK inhibitors; SSc-ILD not approved for IV use.

    inv-211: Adakveo initial therapy

    Adakveo initial therapy

    Adakveo initial: Complete Medicare Part B drug request form; provide medical records; trial of hydroxyurea for 6 months unless intolerant/contraindicated; dosing per FDA labeling; coverage duration 2 years.

    Failure to document 6-month hydroxyurea trial may lead to denial.

    inv-212: Adzynma initial therapy

    Reauthorization and Continuation Criteria

    inv-230: Alhemo reauthorization

    Reauthorization requirements

    Alhemo reauthorization: 1) Patient continues to use Alhemo for routine prophylaxis AND 2) Documentation of clinical benefit (e.g., fewer bleeding episodes, reduced use of factor replacement or bypassing agents) provided.

    Reauthorization duration 12 months.

    inv-231: Adzynma reauthorization

    Adzynma reauthorization requirements

    Adzynma reauthorization: Demonstrate beneficial response to therapy (e.g., decrease in acute/subacute TTP events, improvement in platelet count, decrease in microangiopathic hemolytic anemia episodes); reauthorization duration: 12 months.

    Medical records supporting response required.

    inv-232: Alhemo continuation

    Coding and Key Clinical Thresholds

    Avastin HCPCSHCPCSCovered
    J9035Bevacizumab (Avastin) — chemotherapy (J9035) only
    Beizray referenced HCPCSHCPCS
    J9171Docetaxel (generic docetaxel reference: Taxotere, J9171)
    Bortezomib example HCPCSHCPCS
    J9049generic bortezomib HCPCS code listed as example
    J9041generic bortezomib HCPCS code listed as example
    Docivyx related HCPCSHCPCS
    J9171Docetaxel (generic docetaxel reference, Taxotere, J9171)
    inv-72: ADAMTS13 activity — diagnostic threshold
    ADAMTS13 activityADAMTS13 activity < 10% (diagnostic requirement for cTTP)
    Diagnostic confirmationGenetic testing confirming cTTP and absence of inhibitor antibody (per policy)
    Supporting documentationMedical records including current weight for dosing must be provided for initial and reauthorization requests
    inv-73: Morning serum total testosterone threshold
    Morning serum total testosterone thresholdTwo pre-treatment morning serum total testosterone measurements on separate days < 300 ng/dL (or below laboratory reference range)

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization required for listed Part B drugs

    Prior authorization (PA) is required for Medicare Part B drugs listed in this document; complete the appropriate Medicare Part B PA form (Non‑Oncology or Oncology) or Web Form and submit clinical documentation including dose, frequency, place of administration, and supporting medical records demonstrating prior therapies and responses.

    • Use Medical Drug List (MDL) to verify Part B vs Part D determination.
    • Provide dose, frequency, place of administration for billing.
    Prior Authorization

    Complete Medicare Part B drug request form

    To streamline review providers must complete the Medicare Part B (Non‑Oncology) drug request form or Web Form (or the Oncology drug request form when applicable) when requesting coverage for Part B drugs; include completed form with required clinical documentation.

    • Use Oncology form for chemotherapeutic J9035/J9171 requests when indicated.
    • Complete Web Form to improve timeliness of review.

    Step Therapy Table — Prior Trials Required

    DrugStep therapy requirement
    Actemra (tocilizumab IV)
    Required: trial of preferred agent Tyenne prior to approval (Priority Health Part B Step Therapy Drug).
    DrugStep therapy requirement
    Adakveo (crizanlizumab)
    Required: trial of hydroxyurea for 6 months prior to approval, unless intolerance or contraindication documented. Coverage duration: 2 years.
    Examples / groupsStep therapy requirement
    IVIG products (e.g., Gammagard Liquid, Gamunex-C, Privigen, Asceniv/Bivigam) — Part B determinations
    For requests determined to be a Part B benefit, must first try two preferred IVIG products before approval of the requested IVIG product.
    DrugStep therapy status
    Amvuttra (vutrisiran)
    Not subject to Priority Health Part B step therapy per this policy (Priority Health Part B Step Therapy Drug: No).
    Grouped products / examplesRequired prior trials
    IVIG group (Asceniv, Bivigam, Alyglo)
    Must first try two preferred IVIG products (e.g., Gammagard Liquid, Gamunex-C, Privigen) for Part B determinations before approval.
    CategoryGeneric/alternative trial requirement
    Testosterone products (e.g., Aveed, Azmiro)
    Require trial and failure of generic injectable testosterone (cypionate or enanthate) AND a generic topical testosterone therapy; two pre-treatment morning total testosterone measurements <300 ng/dL required.
    Example biosimilar / genericRequired prior trial
    Tocilizumab (Avtozma / Actemra) and pemetrexed (Axtle)
    Prior trial of lower-cost biosimilars/generics required: Avsola OR Renflexis before tocilizumab biosimilar in most indications; trial of generic pemetrexed required before pemetrexed branded product.
    Drug / kitCMS-aligned step therapy
    Beizray (docetaxel) and Beizray kit
    Must first try generic docetaxel (Taxotere, HCPCS J9171) prior to approval per CMS guidance and Priority Health step therapy policy.
    ProductIVIG step requirement
    Asceniv (IVIG) / Bivigam (IVIG) examples
    For Part B benefit determinations, must first try two preferred IVIG products (e.g., Gammagard Liquid, Gamunex-C, Privigen) before approving Asceniv or other IVIGs.
    ProductPrior trials required
    Avastin (bevacizumab — J9035) / Alymsys (bevacizumab-maly)
    Must first try biosimilars Mvasi AND Zirabev prior to coverage of Avastin (J9035) or Alymsys; criteria applied consistent with LCD L37205.
    DrugCimzia prior trial requirement
    Cimzia (certolizumab)
    Must first try and fail TWO alternative listed therapies (examples: preferred adalimumab product, Rinvoq, Skyrizi, Tyenne, Cosentyx, Otezla, Xeljanz/XR, Yesintek/Selarsdi, or Enbrel) unless contraindicated or not tolerated.
    Drug(s)Prior therapy requirements
    Cinqair (reslizumab) / Cinryze / Conexxence
    Cinqair: must try and fail ICS/LABA plus one other asthma controller in past 6 months and meet eosinophil thresholds; Cinryze: must first try Haegarda; Conexxence: must first try Jubbonti, Enoby, AND Bildyos.
    Products groupedStep therapy requirement
    Cosentyx IV / Docivyx / Durysta
    Cosentyx IV: prior trial of Avsola, Renflexis OR Simponi Aria required; Docivyx: trial of generic docetaxel (Taxotere, J9171) required; Durysta: trial of two topical prostaglandin analogs required prior to implant.
    Product(s)Step therapy subject?
    Amvuttra and selected others
    Amvuttra: Not subject to Priority Health Part B step therapy. Other products listed are subject to step therapy as noted in individual product sections.
    Scenario / examplesRequired prior trial
    Avtozma (tocilizumab biosimilar) / Avsola or Renflexis examples
    Avtozma/Actemra: for most medically accepted indications must first try Avsola OR Renflexis (biosimilars) before approval; generic alternatives required for other agents (e.g., generic pemetrexed for Axtle).

    Quantity Limits and Special Limits

    inv-257: Casgevy quantity limit (1 lifetime dose)
    Casgevy quantity limitLimit: one lifetime dose (authorization limited to a single treatment course)
    Authorization durationAuthorization duration: 6 months (initial)
    Eligibility notesCoverage requires documentation of genotype and clinical history per policy (e.g., SCD or transfusion-dependent beta thalassemia)

    Site of Care and Benefit Determination

    Billing Rule

    Establish Part B vs Part D determination for infusion center billing

    Determine Part B vs Part D benefit for infusion center claims and document the benefit decision on the PA form; Part B vs Part D determinations affect site‑of‑care billing and payment.

    Billing Rule

    Infusion dosing must follow FDA labeling or accepted standards

    Doses for infusion center administration will be approved according to FDA‑approved labeling or accepted standards of medical practice; include dosing details on the PA form.

    Billing Rule

    Document Part B benefit determination for infusion claims

    Biosimilar Use and Interchangeability

    Billing Rule

    Actemra/biosimilar support — FDA‑determined biosimilars supported

    FDA‑determined biosimilars are supported for use and may be used in place of the reference biologic when indicated; reference the policy's biosimilar guidance when selecting products.

    Billing Rule

    Avastin: must try Mvasi and Zirabev first (J9035)

    Avastin biosimilars (Mvasi, Zirabev) must be tried before alternative bevacizumab products; document trials of Mvasi and Zirabev prior to requesting Avastin (J9035) per policy.

    Billing Rule

    Aukelso biosimilar: interchangeable; required prior trials per policy

    Aukelso (denosumab biosimilar to Xgeva) is FDA‑approved for the reference product indications and provisionally interchangeable; policy requires trials of specified alternatives before Aukelso.

    Background and Scope

    Medicare Part B covers outpatient drugs and biologics typically administered by infusion or injection and furnished incident to a physician service. Priority Health follows NCDs/LCDs/LCAs and CMS guidance when developing Part B coverage rules; providers must complete the Medicare Part B (Non‑Oncology) drug request form or Web Form and submit supporting medical records to facilitate prior authorization and benefit determination.

    Key Definitions

    inv-180: Part B drug definition
    Part B drug definitionOutpatient prescription drugs and biologicals administered by infusion or injection, furnished incident to a physician or provider service and not usually self-administered
    Typical administration settingUsually administered in clinical settings (infusion center, office, or hospital outpatient) as Part B benefit
    Benefit determinationPart B vs Part D determination may be required to establish coverage and payment rules
    inv-181: Step Therapy definition
    Step Therapy definitionRequirement to try a preferred or more cost-effective drug before a non-preferred drug; applies to MAPD members not currently receiving the Part B drug
    ApplicationApplied to certain Part B drugs/biologics per CMS guidance; exceptions and specific prior agents are listed per product
    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Part B prior authorization and step therapy criteria for Part B drugs
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionComplete the Medicare Part B drug request form or Web Form and submit supporting medical records including prior therapies and responses to request prior authorization.
    SourceLink
    On This Page
    Coverage Criteria by ProductInitial Therapy Criteria (Product-specific)Reauthorization and Continuation CriteriaCoding and Key Clinical ThresholdsPrior Authorization, Documentation, and Denial RisksStep Therapy Table — Prior Trials RequiredQuantity Limits and Special LimitsSite of Care and Benefit DeterminationBiosimilar Use and InterchangeabilityBackground and ScopeKey Definitions
    Lupus Nephritis initial coverage: Confirmed diagnosis of SLE AND kidney biopsy confirming class 3, 4, and/or 5 disease AND receiving standard therapy for lupus nephritis (e.g., mycophenolate or azathioprine plus a steroid).

    Biopsy and medical records required; initial coverage 1 year.

    Lupus Nephritis reauthorization: Evidence of clinical improvement including improved or stable eGFR must be provided.

    Reauthorization duration 2 years.

    Reauthorization requires decreased signs of TMA and supporting records.

    Myasthenia Gravis initial: 1) Baseline MG-ADL score >= 6; 2) Diagnosis of generalized MG that is AChR-Ab positive; 3) Tried and failed Epysqli; 4) Tried Vyvgart or Vyvgart Hytrulo with intolerance or inadequate response; 5) Bkemv will not be used in combination with similar MG therapies (chronic immune globulin therapy, Vyvgart, Ultomiris, Rystiggo, Zilbrysq); 6) Medical records supporting the request provided.MG-ADL >= 6

    Prescribed by or in consultation with a neurologist; reauthorization requires improvement in MG-ADL.

    Reauthorization requirements: Condition-specific demonstration of clinical improvement from baseline (e.g., decreased relapse rate for NMOSD; increased hemoglobin and reduced transfusions for PNH; normalization of platelets/LDH/creatinine for aHUS; improved MG-ADL for MG) and supporting medical records are required.

    Reauthorization duration 2 years.

    Adzynma initial therapy

    Adzynma initial: Genetic testing confirming cTTP; ADAMTS13 activity <10%; medical records and current weight provided; initial dosing every 2 weeks (may adjust to weekly with documentation); initial approval 12 months.ADAMTS13 <10%

    Lack of genetic testing or ADAMTS13 <10% may lead to denial.

    inv-213: Alhemo initial therapy

    Alhemo initial therapy

    Alhemo initial: Used for routine prophylaxis; hemophilia A patients must have tried and failed Hemlibra; prescriber must be hematologist or specialist; patient ≥12 years for Alhemo Pen; initial approval 12 months.

    Medical records required; reauthorization requires documentation of clinical benefit.

    inv-214: Initial therapy step requirements (product-agnostic)

    Initial therapy and step requirements

    Alyglo initial step: For Part B Alyglo requests, patient must have tried two preferred IVIG products prior to approval (examples: Gammagard Liquid, Gamunex-C, Privigen).
    Alymsys initial step: For Alymsys, patient must have tried Mvasi AND Zirabev prior to approval.

    inv-215: Initial therapy (product-agnostic)

    Initial authorization requirements by indication

    hATTR-PN initial: Pathogenic TTR mutation; PND ≤ IIIb; clinical signs/symptoms of polyneuropathy; age ≥18; required medical records provided.
    ATTR-CM initial: NYHA class I–III with manifestations or prior HF hospitalization; imaging demonstrating increased LV wall thickness; diagnosis confirmed by biopsy/genetics/radionuclide imaging (Grade 2/3 uptake if radionuclide used); must try and fail tafamidis; age ≥18; required records provided.

    inv-216: Initial therapy (IVIG and similar products)

    Initial therapy requirements and step therapy

    Initial therapy general: Requests must be submitted via appropriate Medicare Part B drug request form; required documentation provided; specified prior therapies (two preferred IVIGs, biosimilars, or generic testosterone trials) must be tried and failed as outlined per product.

    Refer to LCDs where applicable.

    inv-217: Initial therapy / step requirements (group)

    Initial therapy / step requirements

    Aveed initial therapy: Requires prior trials of generic injectable testosterone (cypionate or enanthate) AND generic topical testosterone therapy before coverage; two pre-treatment morning testosterone measurements and clinical signs/symptoms required; coverage 2 years.two morning serum total testosterone <300 ng/dL

    Failure to document required trials or testosterone measurements may lead to denial.

    Avgemsi initial therapy: Must first try generic gemcitabine injection before Avgemsi will be approved; medical records required; coverage up to 1 year.
    Avopef initial therapy: Must first try generic etoposide; medical records documenting prior therapies and responses required; coverage 1 year.

    inv-218: Initial therapy/step therapy (group)

    Initial therapy/step therapy

    Avtozma initial: Trial of Avsola OR Renflexis required for most indications except CRS, GCA, and certain COVID-19 scenarios where different guidance applies.
    Axtle initial: Must first try generic pemetrexed prior to Axtle approval.
    Azmiro initial: For hypogonadism must try and fail generic testosterone cypionate; for gender dysphoria documentation per guidelines required.

    inv-219: Beizray initial therapy

    Initial coverage rules for Beizray products

    Beizray Initial: Must first try generic docetaxel (Taxotere, J9171); covered uses are medically accepted indications; coverage duration 1 year; dose per FDA labeling.

    Prior authorization form required.

    inv-220: Benlysta initial therapy

    Initial coverage rules for Benlysta by indication

    SLE Initial: SELENA-SLEDAI ≥6 AND either anti-dsDNA >30 IU/ml or ANA >1:80 AND taking standard therapy that includes two of steroid, immunosuppressant, hydroxychloroquine for ≥12 weeks each; required medical records provided.SELENA-SLEDAI >= 6

    Initial coverage 1 year.

    Lupus Nephritis Initial: Confirmed SLE AND kidney biopsy confirming class 3, 4, and/or 5 disease AND receiving standard LN therapy (e.g., mycophenolate or azathioprine plus steroid); medical records and biopsy required.

    Initial coverage 1 year.

    inv-221: Initial therapy criteria (additional products)

    Initial therapy requirements per product:

    Benlysta Initial: For SLE: must be on standard care including two of steroid, immunosuppressant, hydroxychloroquine for ≥12 weeks each; for LN: must be receiving standard therapy (e.g., mycophenolate or azathioprine plus steroid).12 weeks for SLE prior therapies

    Initial authorization 1 year.

    Bivigam Initial: Provide medical records; covered uses include all medically accepted indications not otherwise excluded; Part B vs Part D determination required; must try two preferred IVIG products first when Part B applies.N/A

    Initial authorization 2 years.

    Bkemv Initial: Indication-specific requirements: e.g., NMOSD requires AQP4 positivity and prior Epysqli failure; PNH requires flow cytometry confirmation and hemolysis-associated symptoms; aHUS requires exclusion of Shiga-toxin HUS and TTP and prior Epysqli failure; myasthenia gravis requires MG-ADL ≥6, AChR-Ab positivity, prior Epysqli and Vyvgart trials/failures.MG-ADL ≥6 for MG

    Initial authorization 1 year.

    inv-222: Initial therapy requirements (group)

    Initial therapy / step requirements per agent

    Bomyntra initial therapy: Must first try Wyost, Xtrenbo, AND Bilprevda prior to Bomyntra approval.

    Step therapy applies.

    Bosaya initial therapy: Must first try Jubbonti, Enoby, AND Bildyos prior to Bosaya approval.

    Step therapy applies.

    Boruzu initial therapy: Must first try one generic bortezomib injectable product (e.g., HCPCS J9049 or J9041) prior to Boruzu approval.

    Step therapy applies.

    Bkemv initial therapy: Patient must have tried and failed Epysqli and tried Vyvgart or Vyvgart Hytrulo with intolerance or inadequate response; baseline MG-ADL ≥6 and AChR-Ab positive MG diagnosis required.

    See Bkemv group for full indication-specific criteria.

    inv-223: Casgevy initial therapy

    Casgevy initial therapy requirements

    Casgevy initial: See Casgevy initial therapy criteria: genetic confirmation, VOE history, weight, organ function, HSCT eligibility, prior hydroxyurea trial or alternative SCD therapy, and other listed requirements; authorization 6 months; one lifetime dose limit.

    Prescriber must be hematologist or appropriate specialist.

    inv-224: Cimzia initial therapy

    Cimzia initial therapy requirements

    Cimzia initial: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; must have tried and failed two listed alternative therapies unless contraindicated or not tolerated; prescriber specialist or consultation required; coverage duration 2 years.

    Medical records required.

    inv-225: Cinqair initial therapy

    Cinqair initial therapy requirements

    Cinqair initial: Medical records supporting the request provided; patient's current weight provided; eosinophil threshold met (≥150 cells/mcL at therapy start OR ≥300 cells/mcL in prior 12 months); tried and failed ICS/LABA plus one other asthma controller in past 6 months; not used in combination with other biologics; coverage duration 2 years.eosinophil criteria

    Failure to provide required documentation may lead to denial.

    inv-226: Cinqair Initial Therapy (duplicate grouping for clarity)

    Initial Cinqair therapy requirements:

    Initial Cinqair: Documentation of prior therapies and responses; current weight; blood eosinophils ≥150 cells/mcL at therapy start OR ≥300 cells/mcL in prior 12 months; trial and failure of 1 ICS/LABA plus 1 other controller in past 6 months (≥4 weeks).see node text

    Dose per FDA labeling; initial and reauthorization duration 2 years.

    inv-227: Step therapy / initial therapy — consolidated

    Step therapy / initial therapy

    Cosentyx initial requirement: Prior trial of Avsola, Renflexis OR Simponi Aria required before Cosentyx IV approval.

    Prescriber must be specialist or consult specialist.

    Docivyx initial requirement: Must first try generic docetaxel (Taxotere, J9171) before Docivyx approval.
    Durysta initial requirement: Must try TWO topical prostaglandin analogs (latanoprost, bimatoprost, travoprost) prior to Durysta.

    inv-228: Initial therapy (gene therapy / specialized)

    Initial coverage requirements

    Elevidys initial requirements: Documentation of DMD confirmed by genetic mutation not involving exon 8 or 9 AND anti-AAVrh74 titer <1:400; prescriber is neurologist or experienced DMD specialist; complete Medicare Part B Non-Oncology drug request form/Web Form; dose per FDA labeling.anti-AAVrh74 titer <1:400

    Elevidys contraindicated with deletions in exon 8 or 9; initial and reauthorization duration 1 year.

    inv-229: Enjaymo initial therapy / dosing

    Enjaymo initial dosing and population notes

    Enjaymo dosing reference: Enjaymo dosing per FDA: 6,500 mg (39 to <75 kg) or 7,500 mg (≥75 kg) IV weekly for two weeks then every two weeks thereafter; initial coverage requires confirmed CAD, recent transfusion, trial and failure of rituximab-containing regimen, symptomatic CAD, and hematologist involvement.

    Initial authorization 6 months; reauthorization requires documented clinical benefit.

    Alhemo continuation / reauthorization

    Continued use: Patient continues on Alhemo for routine prophylaxis and shows documented clinical benefit (fewer bleeds or reduced use of factor/bypassing agents).

    Reauthorization duration 12 months.

    inv-233: Reauthorization (product-agnostic requirement for clinical benefit)

    Reauthorization requires evidence of clinical benefit compared to baseline.

    Continuation/Reauthorization: Provide documentation demonstrating positive clinical response compared to baseline; coverage duration for reauthorization typically 1 year unless otherwise specified.

    Examples and specific measures vary by product/indication (see product-specific reauthorization criteria).

    inv-234: Continuation therapy durations (product list)

    Continuation/renewal coverage limits and durations

    Continuation rules: Coverage durations specified by product (examples: Asceniv 2 years; Aukelso up to 2 years; Avastin up to 1 year; Aveed 2 years); required medical records must be provided for renewals and doses follow FDA labeling or accepted standards.

    Refer to product-specific sections for reauthorization clinical criteria.

    inv-235: Benlysta continuation

    Reauthorization requirements for Benlysta

    SLE Reauthorization: Evidence of clinical improvement since starting Benlysta must be provided.

    Reauthorization period 2 years.

    Lupus Nephritis Reauthorization: Evidence of clinical improvement including improved or stable eGFR must be provided.

    Reauthorization period 2 years.

    inv-236: Reauthorization/Continuation therapy (evidence of improvement)

    Reauthorization requires evidence of clinical improvement from baseline specific to the treated condition.

    Benlysta Reauthorization: Evidence of clinical improvement for SLE or improved/stable eGFR for lupus nephritis is required.N/A

    Reauthorization 2 years.

    Bkemv Reauthorization: Condition-specific clinical improvement (e.g., decreased relapse rate for NMOSD; increased hemoglobin/reduced transfusions for PNH; normalization of platelets/LDH/creatinine for aHUS; improved MG-ADL for myasthenia gravis) is required.N/A

    Reauthorization 2 years.

    inv-237: Bkemv reauthorization

    Bkemv continuation / reauthorization

    Bkemv continuation: Bkemv will not be used in combination with similar MG therapies; documentation of improvement in MG-ADL total score from baseline required; medical records supporting request must be provided.

    Reauthorization duration 2 years.

    inv-238: Cinqair Reauthorization

    Reauthorization conditions where specified:

    Cinqair continuation: Documented clinical benefit (decrease in exacerbations, symptom improvement, decreased oral steroid use) is required for reauthorization.clinical improvement

    Reauthorization duration 2 years.

    inv-239: Reauthorization (general)

    Reauthorization rules

    Reauthorization available annually (1 year) with documentation supporting ongoing medical necessity; follow product-specific reauthorization clinical criteria.

    Example: Elevidys initial and reauthorization duration 1 year.

    inv-240: Enjaymo continuation therapy

    Enjaymo continuation:

    Continuation duration: Initial coverage 6 months; reauthorization 12 months with documented clinical benefit (increase in hemoglobin and decreased transfusions compared to baseline).

    Medical records and labs (baseline Hgb, current weight) required for reauthorization.

    inv-241: Entyvio continuation therapy

    Entyvio continuation:

    Continuation duration: Initial coverage 1 year; reauthorization 2 years with documented positive clinical response (e.g., decreased stool frequency, no blood in stool, decreased steroid use, decreased inflammatory markers).

    Medical records required.

    Required prior trials
    Must have tried and failed generic injectable testosterone (cypionate or enanthate) AND a generic topical testosterone therapy before approval
    Clinical signs requirementClinical signs/symptoms consistent with testosterone deficiency other than erectile dysfunction or decreased libido are required
    inv-74: Total testosterone threshold
    Total testosterone diagnostic cut-offTotal testosterone < 300 ng/dL is the reasonable cut-off to support diagnosis of low testosterone
    Confirmatory testingLevels should be obtained on two or more separate mornings due to diurnal variation
    Correlation with symptomsLow total testosterone should be accompanied by signs/symptoms of deficiency to establish diagnosis
    inv-75: Pre-treatment morning serum total testosterone (two measurements)
    Pre-treatment requirementTwo pre-treatment morning serum total testosterone measurements on separate days < 300 ng/dL (or low per laboratory reference) are required prior to coverage
    TimingMeasurements must be taken on separate mornings to account for diurnal variation
    DocumentationMedical records must document both values and accompanying clinical signs/symptoms
    inv-76: SELENA-SLEDAI threshold
    SELENA-SLEDAI thresholdSELENA-SLEDAI score ≥ 6 required for Benlysta SLE initial coverage
    Associated antibody criteriaEither anti-dsDNA antibody > 30 IU/ml OR ANA titer > 1:80 in conjunction with SELENA-SLEDAI ≥ 6
    Prior therapy requirementPatient must be receiving standard therapy including at least two of: steroid, immunosuppressant, hydroxychloroquine for ≥12 weeks each
    inv-77: anti-dsDNA antibody threshold
    anti-dsDNA antibody thresholdAnti-dsDNA antibody > 30 IU/ml (used with SELENA-SLEDAI ≥ 6 for Benlysta SLE initial coverage)
    ContextUsed as part of diagnostic criteria for active SLE when combined with disease activity score and standard therapy
    DocumentationLaboratory result must be included in medical records submitted for prior authorization
    inv-78: ANA titer threshold
    ANA titer thresholdANA titer > 1:80 (used with SELENA-SLEDAI ≥ 6 for Benlysta SLE initial coverage)
    Role in criteriaOne of the serologic markers required to demonstrate active SLE alongside disease activity score
    Submission requirementProvide ANA titer result in supporting medical records for initial authorization
    inv-79: eosinophil threshold for Cinqair
    Eosinophil threshold at therapy startBlood eosinophils ≥ 150 cells/mcL at therapy start (Cinqair)
    Alternative prior measurementOR blood eosinophils ≥ 300 cells/mcL in the previous 12 months
    DocumentationEosinophil counts must be provided in medical records submitted for prior authorization
    inv-80: transfusion dependence (beta thalassemia) definition
    Transfusion dependence definitionTransfusion dependent beta thalassemia defined as history of ≥100 mL/kg/year OR ≥10 units/year of packed red blood cells in the previous 2 years
    DocumentationMedical records must document transfusion history for eligibility (prior 2-year period)
    Additional requirementsNo known/available HLA-matched donor and provider attestation patient would be eligible for HSCT if donor unavailable (for Casgevy)
    inv-81: Blood eosinophils (duplicate clinical threshold)
    Blood eosinophils (duplicate threshold)Blood eosinophils ≥150 cells/mcL at therapy start OR ≥300 cells/mcL in the previous 12 months (used for severe eosinophilic asthma/Cinqair)
    Clinical contextApplies to add-on biologic therapy for severe eosinophilic asthma when prior controller therapy has failed
    Required recordsProvide eosinophil counts and documentation of prior controller therapy trial(s) in the past 6 months
    inv-82: Coverage duration (Cosentyx IV)
    Coverage duration (Cosentyx IV)Coverage duration: 2 years for Cosentyx IV
    Prescriber requirementPrescriber must be a specialist or have consulted with a specialist
    Prior trialMust first try Avsola, Renflexis OR Simponi Aria before Cosentyx IV approval
    inv-83: Coverage duration (Docivyx)
    Coverage duration (Docivyx)Coverage duration: 1 year for Docivyx
    Prior trial requirementMust first try generic docetaxel (Taxotere, J9171) before Docivyx approval
    DocumentationMedical records supporting the request must be provided; dose per FDA labeling
    Prior Authorization

    Adakveo prior authorization — hydroxyurea trial required

    Adakveo (crizanlizumab) requires prior authorization; requests must document a trial of hydroxyurea for 6 months or an intolerance/contraindication to hydroxyurea. Coverage is authorized for up to 2 years.

    • Provide medical records supporting trial of hydroxyurea or reason for not using hydroxyurea.
    • Include dose and administration details per FDA labeling.
    Prior Authorization

    Adzynma prior authorization — genetic and ADAMTS13 result required

    Adzynma (rADAMTS13) requires prior authorization with genetic testing confirming congenital TTP (cTTP) and documentation of ADAMTS13 activity <10% for initial approval; include current weight for dosing. Initial and reauthorization approvals are 12 months.

    • Submit genetic testing confirming cTTP.
    • Include ADAMTS13 activity value (<10%) and current weight for dosing.
    Prior Authorization

    Alhemo prior authorization and reauthorization documentation

    Alhemo requires prior authorization for routine prophylaxis in hemophilia A or B; initial requests for hemophilia A must include documentation of Hemlibra failure; reauthorization requires documentation of clinical benefit (fewer bleeds or reduced use of replacement/bypassing agents).

    • Provide medical records documenting prior Hemlibra trial and reason for failure (hemophilia A).
    • For reauthorization, include evidence of clinical benefit (e.g., reduced bleeding events).
    Prior Authorization

    Submit appropriate PA form (Alyglo/Alymsys examples)

    Providers should complete the Medicare Part B drug request form or Web Form for products such as Alyglo (Non‑Oncology) or Alymsys (Oncology) and submit supporting medical records documenting prior therapies and responses to streamline review.

    • Use the Oncology Drug Request form for Alymsys (bevacizumab biosimilar) when applicable.
    • Attach medical records showing prior therapies and responses.
    Prior Authorization

    PA required — include medical records and prior therapy documentation

    Prior authorization via the Medicare Part B (Non‑Oncology) drug request form or Web Form is required for the Part B drugs in this document; include required medical records and prior therapy documentation with the request.

    • Ensure Part B vs Part D determination is clear on the form.
    • Attach prior therapy history and response documentation.
    Prior Authorization

    PA required — dose per FDA labeling for IVIG and infusions

    For IVIG and other infusion products, prior authorization is required and dose will be approved per FDA labeling or accepted standards of medical practice; submit the Medicare Part B drug request form or Web Form with supporting records.

    • Include indication, dosing, and administration site for billing.
    • For IVIG Part B requests include documentation of prior IVIG trials when applicable.
    Prior Authorization

    Prior authorization required — grouped products

    This group of Part B biologics requires prior authorization; complete the Medicare Part B drug request form or Web Form and submit documentation of prior therapies and treatment responses with the request.

    • For biosimilar groups, include evidence of trials of required biosimilars/generics per product-specific step therapy rules.
    • Ensure prescriber specialty is documented when required.
    Prior Authorization

    Prior authorization plus step therapy designation — complete PA form

    These Part B drugs are designated as Priority Health Part B Step Therapy Drugs and require prior authorization; complete the Medicare Part B drug request form or Web Form and show evidence of required prior trials per product-specific rules.

    • Follow the product-specific step therapy requirements (e.g., Avtozma/Actemra biosimilar trials).
    • Attach documentation showing failure/intolerance of required prior agents.
    Prior Authorization

    Use correct PA form (Oncology vs Non‑Oncology)

    Complete the appropriate Medicare Part B Oncology (Cancer Therapy) or Non‑Oncology drug request form or Web Form when requesting coverage to ensure all billing and clinical fields are provided; oncology drugs (e.g., J9035, J9171) should use the Oncology form when applicable.

    • Provide HCPCS/HCPCS code (e.g., J9035 for Avastin, J9171 for docetaxel) and indication.
    • Include prior therapy and response documentation.
    Prior Authorization

    PA required — include supporting records and evidence

    Prior authorization is required for the listed Part B agents; requests must include supporting medical records and evidence of prior therapies and responses to treatment.

    • Include diagnostic tests, lab values, and specialist consultation notes when relevant.
    • Document prior treatments and their outcomes.
    Prior Authorization

    Prior authorization required — biosimilars and specialty agents

    Prior authorization via the Medicare Part B drug request form or Web Form is required for Bomyntra, Boruzu, Bosaya, and Bkemv‑related requests; include medical records and documentation of prior therapy trials as specified.

    • For Bkemv, include documentation of Epysqli/Vyvgart trials and baseline MG‑ADL when applicable.
    • Provide prior therapy failure documentation per product.
    Prior Authorization

    Casgevy prior authorization — one lifetime dose, 6‑month auth

    Casgevy requires completion of the Medicare Part B (Non‑Oncology) drug request form or Web Form and submission of supporting medical records; authorization is for 6 months and limited to a single lifetime treatment.

    • Document genotype for SCD (βS/βS, βS/β0, or βS/β+), VOE history, current weight, and HSCT eligibility.
    • For beta thalassemia, include transfusion history (≥100 mL/kg/year or ≥10 units/year) and donor availability assessment.
    Prior Authorization

    Cimzia prior authorization — step therapy and combination exclusion

    Cimzia requires prior authorization via the Medicare Part B drug request form or Web Form with documentation that the patient tried and failed two listed alternative therapies and prescriber is a specialist or consulted one; do not combine with other biologics, Otezla, or JAK inhibitors.

    • Submit documentation of trials/failures of two listed alternatives (e.g., preferred adalimumab, Rinvoq, Skyrizi).
    • Do not submit requests supporting combination biologic/JAK/Otezla use.
    Prior Authorization

    Cinqair prior authorization — weight and eosinophil data required

    Cinqair requires prior authorization; include the Medicare Part B drug request form or Web Form, medical records documenting prior controller therapy trials, current weight, and blood eosinophil counts meeting threshold criteria.

    • Provide eosinophil count ≥150 cells/mcL at therapy start OR ≥300 cells/mcL in prior 12 months.
    • Document trial/failure of ICS/LABA plus another controller within past 6 months.
    Prior Authorization

    Complete PA form and attach supporting records

    Complete the Medicare Part B (Non‑Oncology) drug request form or Web Form for all Part B requests; fill required fields and attach supporting medical records to enable timely PA review.

    • Ensure documentation of prior therapies, labs, and dosing is attached.
    • Use Oncology form when the drug is a chemotherapy product.
    Step Therapy

    Conexxence step therapy — document required prior trials

    Conexxence (denosumab biosimilar) is subject to Part B step therapy; prior authorization must show trials of required agents before approval.

    • Document trials of Jubbonti, Enoby, AND Bildyos as required before Conexxence.
    • Include medical records and justification if step therapy cannot be met.
    Prior Authorization

    PA required — Cosentyx, Docivyx, Durysta examples

    Prior authorization is required via the Medicare Part B (Non‑Oncology) drug request form or Web Form for Cosentyx, Docivyx, Durysta and similar agents; include supporting medical records and prior therapy documentation.

    • For Cosentyx IV include prescriber specialty and prior biosimilar trial documentation.
    • For Docivyx include trial of generic docetaxel (J9171).
    Prior Authorization

    PA required — Elevidys genetic and antibody prerequisites

    Prior authorization is required and, for Elevidys, must document genetic confirmation of DMD that is not a deletion in exon 8 or exon 9 and an anti‑AAVrh74 titer <1:400 on the PA form or Web Form.

    • Attach genetic testing confirming DMD without exon 8/9 deletions.
    • Provide anti‑AAVrh74 total binding antibody titer (<1:400).
    Prior Authorization

    Complete PA form for Enjaymo/Entyvio — attach labs

    Complete the Medicare Part B (Non‑Oncology) drug request form or Web Form to streamline review for Enjaymo, Entyvio, and other Part B agents; attach required clinical documentation and labs.

    • Use the Web Form and include clinical labs (e.g., baseline hemoglobin for Enjaymo).
    • Provide prior therapy history and specialist consult notes as required.
    Prior Authorization

    Enjaymo PA — CAD diagnosis, transfusion, rituximab trial required

    Enjaymo prior authorization requires documentation of confirmed cold agglutinin disease (CAD), at least one blood transfusion within 6 months prior to initiation, a documented trial and failure of a rituximab‑containing regimen, presence of CAD‑related symptoms, age ≥18, and that the prescriber is or consulted a hematologist.

    • Provide transfusion record within prior 6 months.
    • Attach documentation of rituximab‑containing regimen trial and failure and baseline hemoglobin.
    Step Therapy

    Entyvio step therapy — Avsola or Renflexis trial required

    Entyvio requires prior trial of Avsola OR Renflexis before approval (Part B step therapy); the prescriber must be a specialist or have consulted with one and documentation of prior trial must be included with the PA request.

    • Document trial and failure/intolerance of Avsola OR Renflexis.
    • Include specialist consultation note from gastroenterology when applicable.
    Step Therapy

    Step therapy — Actemra IV requires trial of Tyenne first

    Priority Health applies Part B step therapy per CMS guidance; Actemra IV is a Part B step therapy drug and requires trial of the preferred agent Tyenne before approval.

    • Document trial and failure or intolerance of Tyenne.
    • Attach medical records demonstrating trial period and outcome.
    Step Therapy

    Adakveo step therapy — hydroxyurea trial required

    Adakveo step therapy: prior authorization will require documentation that the member tried hydroxyurea for 6 months or has an intolerance/contraindication to hydroxyurea prior to approval of Adakveo.

    • Provide clinical notes showing 6 months of hydroxyurea use or documentation of intolerance/contraindication.
    • If hydroxyurea was not tried, include rationale and supporting records.
    Step Therapy

    Alyglo Part B step therapy — try two preferred IVIGs first

    For Alyglo determined to be a Part B benefit, the patient must first try two preferred IVIG products (examples: Gammagard Liquid, Gamunex‑C, Privigen) before Alyglo will be approved.

    • Document trials of two preferred IVIG products and outcomes.
    • Attach IVIG administration records and response documentation.
    Step Therapy

    Alymsys step therapy — Mvasi and Zirabev required first

    Alymsys (bevacizumab‑maly) requires trying Mvasi AND Zirabev prior to approval; include documentation of those biosimilar trials with the PA request.

    • Provide records showing trials of Mvasi and Zirabev and treatment outcomes.
    • If trials cannot be completed, include justification.
    Step Therapy

    General Part B step therapy policy — document trials/failures

    Priority Health applies Part B step therapy consistent with CMS guidance to certain drugs/biologics; when step therapy applies, providers must document trials and failures (or intolerance) of required preferred or biosimilar agents on the PA form.

    • Attach documentation of trial duration and clinical response for required agents.
    • For exceptions, submit supporting medical evidence with the PA request.
    Note

    Part B step therapy status — Amvuttra not subject to ST

    This policy notes that Amvuttra is not subject to Part B step therapy per Priority Health; however providers must still submit required medical records and meet other coverage criteria.

    • Provide required diagnostic documentation per Amvuttra criteria.
    • Ensure exclusions (primary amyloidosis; combination with TTR stabilizers) are considered.
    Step Therapy

    Step therapy examples — IVIG, Aukelso, Avastin

    Step therapy applies to products such as Asceniv (IVIG) — for Part B determinations the patient must first try two preferred IVIGs; Aukelso requires trials of Wyost, Xtrenbo, and Bilprevda; Avastin (J9035) requires Mvasi and Zirabev first.

    • Document prior use of the specified preferred products before PA submission.
    • Refer to LCD L34771 or L37205 as applicable.
    Step Therapy

    Step therapy/diagnostic requirements — Aveed and testosterone products

    For Aveed and other testosterone products, prior authorization requires trials of generic injectable testosterone and a generic topical testosterone and two pre‑treatment morning serum total testosterone measurements <300 ng/dL on separate days; include these data on the PA form.

    • Attach records of trials of generic testosterone cypionate/enanthate and topical testosterone.
    • Provide two morning serum total testosterone values <300 ng/dL on separate days and clinical signs/symptoms.
    Step Therapy

    Beizray step therapy — try generic docetaxel (J9171) first

    Beizray and Beizray kit require trial of generic docetaxel (Taxotere, HCPCS J9171) before approval; include documentation of the generic docetaxel trial with the PA request.

    • Provide administration records for generic docetaxel (J9171) and treatment response.
    • If generic trial not feasible, submit justification and supporting evidence.
    Step Therapy

    IVIG Part B step therapy — try two preferred IVIGs first

    For IVIG Part B determinations (e.g., Bivigam, Asceniv), prior authorization requires documentation that the patient tried two preferred IVIG products before approval; include those trial records on the PA form.

    • List the two preferred IVIG products tried and dates administered.
    • Provide clinical response and reason for switching to the requested IVIG.
    Step Therapy

    Step therapy — oncology and complement/biosimilar products

    Step therapy applies to several oncology and specialty agents (e.g., Bomyntra, Bosaya, Boruzu, Bkemv) — providers must document required prior trials (examples: Wyost/Xtrenbo/Bilprevda; generic bortezomib J9049 or J9041; Epysqli/Vyvgart for Bkemv) with the PA request.

    • For Bkemv include baseline MG‑ADL and documentation of Epysqli and Vyvgart trials/failures.
    • For Boruzu include trial of a generic bortezomib injectable (J9049 or J9041).
    Step Therapy

    Cimzia step therapy — two alternative agents required

    Cimzia step therapy: prior authorization must document failure of two listed alternative therapies (preferred adalimumab product, Rinvoq, Skyrizi, Tyenne, Cosentyx, Otezla, Xeljanz, Yesintek/Selarsdi, or Enbrel) before approval unless contraindicated or not tolerated.

    • Attach records showing trials and reason for discontinuation/intolerance.
    • Include specialist consultation notes.
    Step Therapy

    Cinqair step therapy — controller trial and eosinophil threshold

    Cinqair requires prior trial and failure of 1 ICS/LABA plus one other asthma controller in the past 6 months before approval; include documentation of that trial and the eosinophil counts on the PA request.

    • Document controller medications tried (dates/doses) and outcome after ≥4 weeks.
    • Provide eosinophil counts meeting ≥150 cells/mcL at start OR ≥300 cells/mcL in prior 12 months.
    Step Therapy

    Cosentyx IV step therapy and combination exclusion

    Cosentyx IV requires prior trial of Avsola, Renflexis OR Simponi Aria before approval; do not use Cosentyx in combination with other biologic drugs, Otezla, or JAK inhibitors — include prior biosimilar trial documentation and prescriber specialty on the PA form.

    • Attach records of trial of Avsola OR Renflexis OR Simponi Aria and failure/intolerance documentation.
    • Provide specialist consultation note per prescriber restriction.
    Step Therapy

    Enjaymo/Entyvio — Part B step therapy designation and trials

    Priority Health Part B Step Therapy Drugs include Enjaymo and Entyvio; Enjaymo is designated a Part B step therapy drug and Entyvio requires prior trial of Avsola OR Renflexis before approval.

    • For Enjaymo, include transfusion and rituximab trial documentation.
    • For Entyvio, include documentation of Avsola or Renflexis trial.
    Documentation Required

    Required submission documents — complete PA form and provide clinical records

    Providers must submit required documents with PA requests: the Medicare Part B (Non‑Oncology) drug request form or Web Form, dose/frequency/place of administration, and supporting medical records documenting diagnoses, prior therapies, and responses.

    • Include lab values, imaging, genetic test results, and specialist notes as applicable.
    • Ensure billing fields are completed to avoid processing delays.
    Documentation Required

    Required medical records — include diagnosis, prior therapies, weight

    Medical records supporting PA requests must be provided for initial and reauthorization requests; include diagnosis confirmation, prior therapies and responses, current weight (for dosing), and any required diagnostic testing.

    • For drug‑specific requirements include genetic tests (Adzynma), transfusion history (Enjaymo), or antibody titers (Elevidys).
    • Attach documentation of prior therapy failures or intolerances.
    Documentation Required

    Attach prior therapy response documentation with PA

    For many products providers must include documentation of prior therapies and responses with the PA request; this includes trials of specific generics/biosimilars where step therapy applies.

    • Examples: Mvasi and Zirabev trials before Alymsys; two preferred IVIGs before Alyglo.
    • If prior trials not performed, include medical justification and supporting evidence.
    Documentation Required

    Alhemo reauthorization — require documentation of clinical benefit

    For Alhemo reauthorization, providers must submit documentation demonstrating clinical benefit (e.g., fewer bleeding episodes or reduced use of factor replacement or bypassing agents) to support continued coverage.

    • Provide bleed frequency data and replacement therapy utilization pre‑ and post‑Alhemo.
    • Include hematology specialist notes supporting continued use.
    Documentation Required

    Initial hATTR‑PN documentation required

    Initial hATTR‑PN requests must include medical records confirming a pathogenic TTR mutation, baseline PND score ≤ IIIb, and clinical signs/symptoms of polyneuropathy; include these documents on the PA form.

    • Attach genetic testing showing pathogenic TTR mutation.
    • Provide baseline PND score and clinical exam notes describing neuropathy.
    Documentation Required

    Initial ATTR‑CM documentation and tafamidis trial required

    Initial ATTR‑CM requests must include NYHA class I–III heart failure documentation, ECHO or CMR evidence of increased LV wall thickness, confirmatory diagnostic testing (biopsy, genetic testing, or radionuclide imaging), and if radionuclide imaging used include Grade 2 or 3 uptake; also document prior trial and failure of tafamidis.

    • Attach ECHO/CMR reports, biopsy or genetic results, and radionuclide imaging reports if used.
    • Provide documentation of tafamidis trial and reason for failure.
    Documentation Required

    Reauthorization documentation — show clinical benefit vs baseline

    For reauthorization of hATTR‑PN and ATTR‑CM, submit documentation demonstrating positive clinical response compared to baseline (e.g., improved neuropathy symptoms, motor function, QoL, or reduced CV hospitalizations); reauthorization duration is 1 year.

    • Compare baseline and current clinical measures (PND, functional tests, hospitalizations).
    • Include specialist notes documenting improvement.
    Documentation Required

    Submit the Medicare Part B drug request form with documentation

    To streamline review, complete the Medicare Part B (Non‑Oncology) drug request form or Web Form and include the submission form with the clinical documentation.

    • Completing the form helps ensure required billing and clinical fields are provided.
    • Attach the form to all supporting medical records.
    Documentation Required

    Aveed/Azmiro required information — testosterone trials and labs

    Required medical information for hypogonadism (Aveed/Azmiro) includes trials of specified generic testosterone products, two pre‑treatment morning serum total testosterone values on separate days <300 ng/dL, and clinical signs/symptoms consistent with testosterone deficiency; include these on the PA request.

    • Provide dates and outcomes of trials of generic injectable and topical testosterone.
    • Attach two morning testosterone lab results and clinical notes describing symptoms.
    Documentation Required

    Benlysta — attach disease‑specific diagnostics and prior therapy data

    Providers must attach medical records and disease‑specific documentation (e.g., SELENA‑SLEDAI, anti‑dsDNA, ANA titer, kidney biopsy for lupus nephritis) when requesting Benlysta; include these diagnostic results on the PA form.

    • For SLE include SELENA‑SLEDAI ≥6 and antibody evidence (anti‑dsDNA >30 IU/ml or ANA >1:80) and documentation of prior standard‑of‑care therapies for ≥12 weeks.
    • For lupus nephritis attach kidney biopsy showing class 3, 4, and/or 5 disease and eGFR data.
    Documentation Required

    Bkemv documentation — prior trials and reauth improvement required

    For Bkemv requests, include medical records documenting prior therapies and, for reauthorization, objective evidence of clinical improvement (e.g., improvement in MG‑ADL for myasthenia gravis); do not use Bkemv in combination with similar MG therapies.

    • Provide baseline MG‑ADL and follow‑up MG‑ADL demonstrating improvement for reauthorization.
    • Attach documentation of prior Epysqli and Vyvgart/Vyvgart Hytrulo trials and outcomes.
    Documentation Required

    Casgevy required medical records — genotype, weight, HSCT eligibility

    Required Medical Records for Casgevy: submit diagnosis confirmation, prior therapies, organ function status, current weight, and HSCT eligibility assessment; Casgevy is not covered for patients with prior HSCT or prior gene therapy.

    • Attach genetic confirmation of SCD genotype or transfusion history for beta thalassemia.
    • Provide HSCT eligibility attestation and organ function labs.
    Documentation Required

    Cinqair required records — weight, eosinophils, prior controller trial

    For Cinqair, provide medical records documenting prior controller therapy trials and responses, current weight, and blood eosinophil counts meeting thresholds; for reauthorization include documentation of clinical benefit (fewer exacerbations, reduced steroid use).

    • Attach eosinophil counts (≥150 cells/mcL at start OR ≥300 in prior 12 months).
    • Provide documentation of prior ICS/LABA plus another controller trial and outcome.
    Documentation Required

    Reauthorization documentation — demonstrate clinical benefit vs baseline

    For reauthorization requests generally, providers must submit documentation of clinical benefit compared to baseline (e.g., decreased exacerbations, improved function, reduced hospitalizations) to support continued coverage.

    • Compare baseline and on‑therapy measures relevant to the indication.
    • Include objective measures where available (lab tests, hospitalizations, functional scores).
    Documentation Required

    Cosentyx IV — prescriber restriction and prior biosimilar trial required

    Cosentyx IV prescriber must be a specialist or have consulted a specialist; include the specialist’s documentation and prior biosimilar trial evidence (Avsola, Renflexis, or Simponi Aria) on the PA form and do not combine Cosentyx with other biologics, Otezla, or JAK inhibitors.

    • Attach specialist consultation note.
    • Provide records of prior Avsola/ Renflexis/ Simponi Aria trial and failure/intolerance.
    Documentation Required

    Elevidys coverage prerequisites — genetic test and anti‑AAVrh74 titer

    Documentation for Elevidys must include genetic confirmation of DMD that is not a deletion in exon 8 or exon 9 and an anti‑AAVrh74 titer <1:400; include these results with the PA request to avoid denial.

    • Attach genetic testing report confirming DMD and absence of exon 8/9 deletions.
    • Include anti‑AAVrh74 total binding antibody titer (<1:400) result.
    Documentation Required

    Enjaymo reauthorization and initial lab/weight requirements

    Enjaymo reauthorization requires documentation of clinical benefit (increase in hemoglobin and decrease in transfusions compared to baseline); initial PA must include current weight and baseline hemoglobin.

    • Provide transfusion history and Hgb trends pre‑ and post‑therapy.
    • Attach baseline labs and weight for dosing.
    Documentation Required

    Submission form — include dose, frequency, place of administration

    Complete the Medicare Part B (Non‑Oncology) drug request form or Web Form and include required submission documents (dose, frequency, place of administration) with the PA to streamline review and reduce denial risk.

    • Ensure required billing fields are completed and clinical documents attached.
    • Use the Web Form when available to expedite processing.
    Denial Risk

    Denial risk — unsupported exceptions or missing documentation

    Requests that do not meet coverage criteria or lack supporting medical records or medical literature evidence risk denial; submit complete documentation or an exception rationale with supporting evidence to avoid denial.

    • If requesting an exception include peer‑reviewed literature or specialist rationale.
    • Incomplete documentation commonly triggers denial.
    Denial Risk

    Adakveo denial risk — lack of hydroxyurea trial

    Failure to document a 6‑month trial of hydroxyurea (or an intolerance/contraindication) will likely result in denial for Adakveo requests.

    • Include clinical notes documenting hydroxyurea use and response for 6 months or rationale for not using it.
    Denial Risk

    Adzynma denial risk — missing genetic/ADAMTS13 data

    For Adzynma, absence of genetic testing confirming cTTP or ADAMTS13 activity <10% may result in denial; include the genetic test report and ADAMTS13 activity result with the PA.

    • Attach genetic testing confirming cTTP.
    • Provide ADAMTS13 activity value (<10%).
    Denial Risk

    Alhemo denial risks — prior Hemlibra and reauth benefit documentation

    For Alhemo initial requests in hemophilia A, lack of documentation that the patient tried and failed Hemlibra may lead to denial; for reauthorization, absence of documented clinical benefit may trigger denial.

    • Provide Hemlibra trial records or justification for not using Hemlibra.
    • For reauth include bleed reduction or reduced factor use evidence.
    Denial Risk

    Alyglo denial risk — missing two preferred IVIG trials

    Failure to try two preferred IVIG products for Part B‑determined Alyglo requests may trigger denial; include records of the two preferred IVIG trials when submitting the PA.

    • List products and dates of prior IVIG trials (e.g., Gammagard Liquid, Gamunex‑C).
    • Document response or intolerance to those products.
    Denial Risk

    Alymsys denial risk — missing Mvasi and Zirabev trials

    For Alymsys, failure to document trials of Mvasi AND Zirabev prior to requesting Alymsys may lead to denial; include these biosimilar trial records with the PA.

    • Attach administration records for Mvasi and Zirabev and clinical response documentation.
    • If unavailable, include justification and evidence supporting exception.
    Denial Risk

    Amvuttra exclusion — primary amyloidosis not approved

    Use of Amvuttra in patients with primary (light‑chain) amyloidosis will not be approved; requesting Amvuttra for primary amyloidosis risks denial.

    • Confirm diagnosis is hereditary or wild‑type ATTR (not primary light‑chain amyloidosis).
    • Do not submit requests for primary amyloidosis.
    Denial Risk

    Amvuttra denial risk — combination therapy with TTR agents

    Requests for Amvuttra that seek combined use with TTR stabilizers (e.g., tafamidis) or TTR‑lowering agents (e.g., Onpattro) may be denied; do not request combination therapy without strong supporting evidence.

    • Document prior tafamidis trial and reason for failure when requesting Amvuttra as monotherapy.
    • Avoid combination therapy requests unless supported by peer‑reviewed evidence.
    Denial Risk

    Documentation deficiency — common denial trigger

    Lack of medical records supporting the request — including prior therapies and responses — is a common denial trigger; always attach complete clinical documentation to the PA form.

    • Include diagnostic test results, specialist notes, and treatment timelines.
    • Incomplete submissions will delay or result in denial.
    Denial Risk

    Aveed denial triggers — missing testosterone trials or labs

    For Aveed (testosterone) denial triggers: failure to document trials of generic injectable and topical testosterone, absence of two pre‑treatment morning total testosterone values <300 ng/dL on separate days, or lack of required clinical signs/symptoms may lead to denial.

    • Attach records of trials of injectable and topical generic testosterone and two morning testosterone labs.
    • Document clinical signs/symptoms consistent with testosterone deficiency beyond erectile dysfunction/decreased libido.
    Denial Risk

    Avgemsi denial trigger — missing generic gemcitabine trial

    For Avgemsi/Avgemsi, lack of documentation showing a prior trial of generic gemcitabine injection may result in denial; include those records with the PA.

    • Provide generic gemcitabine administration records and outcomes.
    • If generic not used, include rationale and supporting documentation.
    Denial Risk

    Avopef denial trigger — missing generic etoposide trial

    For Avopef, failure to document prior therapy and response (including trial of generic etoposide) may result in denial; attach those trial records to the PA.

    • Include dates, doses, and response to generic etoposide.
    • Provide justification if generic trial not possible.
    Denial Risk

    Avtozma combination exclusion — do not combine with biologics/Otezla/JAKis

    For Avtozma, use in combination with other biologic drugs, Otezla, or JAK inhibitors is an exclusion and may trigger denial; ensure PA requests do not propose concurrent use of these agents.

    • Do not request approval for Avtozma in combination with other biologics, Otezla, or JAKis.
    • If combination is clinically necessary, submit peer‑reviewed evidence and rationale for exception.

    Make a Part B benefit determination (Part B vs Part D) for each infusion request; document this determination and include it with the PA submission to ensure correct benefit and payment processing.

    Billing Rule

    Site of care and administration setting must be specified

    Administration settings (infusion center, office, hospital outpatient) are subject to Part B coverage rules; include place of administration on the PA form and follow FDA labeling or accepted standards for dosing and administration.

    Billing Rule

    Part B infusion products: site‑of‑care determination required

    For Part B infusion products (e.g., IVIG, Bkemv), site‑of‑care determinations (Part B vs Part D) are required and may affect management and payment; document site and benefit decision on the PA form.

    Billing Rule

    Avastin biosimilar trial requirement (Mvasi/Zirabev)

    Avastin biosimilars Mvasi and Zirabev are preferred biosimilars and must be tried before Avastin (J9035) per step therapy; document prior biosimilar trials on the PA form.

    Billing Rule

    Actemra/Avtozma biosimilar: Avsola/Renflexis trial required

    Actemra/Avtozma biosimilar guidance: Avtozma is FDA‑determined highly similar to Actemra; covered for medically accepted indications but step therapy requires trial of Avsola OR Renflexis for most indications.

    Billing Rule

    Avtozma biosimilar — step therapy and documentation note

    Avtozma (tocilizumab‑anoh) is covered as a biosimilar to Actemra; follow the policy's step therapy requirement (Avsola or Renflexis trial) and document prior biosimilar trials on the PA.

    Billing Rule

    Bkemv interchangeability with Soliris — document and follow safety guidance

    Bkemv is FDA‑designated interchangeable with Soliris (eculizumab) and may be used in place of the reference product; document interchangeability and follow related safety guidance (boxed warning for meningococcal infection).

    Billing Rule

    Bkemv: interchangeable biosimilar — include safety/risk mitigation documentation

    Bkemv interchangeability and biosimilar designation is noted in policy; ensure required vaccination/risk mitigation and supporting documentation are included with PA requests.

    Billing Rule

    Bomyntra biosimilar to Xgeva — trial requirements apply

    Bomyntra is a biosimilar to Xgeva and is provisionally determined interchangeable; follow the policy's step therapy requirements and document prior biosimilar trials.

    Billing Rule

    Bosaya biosimilar to Prolia — follow prior trial requirements

    Bosaya is a biosimilar to Prolia and is provisionally determined interchangeable; document required prior trials per policy before requesting the reference or biosimilar product.

    Billing Rule

    Conexxence biosimilar: interchangeable — document prior trials

    Conexxence (Prolia biosimilar) is FDA‑approved for the reference product indications and provisionally interchangeable; follow the policy's step therapy and trial requirements and document prior agent trials on the PA form.

    Billing Rule

    Entyvio: document Avsola or Renflexis trial before Entyvio PA

    Entyvio requires a prior trial of Avsola OR Renflexis per Part B step therapy; document the prior biosimilar trial when submitting the PA request for Entyvio.

    Provider actionDocument trials and failures of required prior agents in medical records submitted with PA request
    inv-182: Prior Authorization definition
    Prior Authorization definitionAuthorization process where certain criteria must be met before a drug may be approved for coverage under Priority Health Medicare; may require Medical Drug List reference and PA forms
    FormsComplete the Medicare Part B (Non-Oncology) drug request form or Web Form (or Oncology form where applicable) to streamline review
    DocumentationSubmit supporting medical records including dose, frequency, place of administration, and prior therapy history as required
    inv-183: Vaso-occlusive crisis (VOC) definition
    Vaso-occlusive crisis (VOC) definitionPain resulting from tissue ischemia caused by vaso-occlusion commonly occurring in bones and bone marrow, often presenting as sudden onset extremity, chest, or back pain
    Clinical relevanceVOC is the common manifestation of sickle cell disease and a key endpoint for therapies like Adakveo and Casgevy
    Supporting guidanceHydroxyurea is recommended with expected clinical response over 3–6 months; a 6-month trial is recommended prior to declaring failure
    inv-184: cTTP definition
    cTTP definitionCongenital thrombotic thrombocytopenic purpura (cTTP) is a rare blood disorder caused by ADAMTS13 deficiency confirmed by genetic testing and ADAMTS13 activity <10% without an inhibitor antibody
    Diagnostic confirmationGenetic testing for ADAMTS13 variants and severely deficient ADAMTS13 activity (<10%) confirm diagnosis
    Prescriber requirementMust be prescribed by or in consultation with a specialist for the disease state
    inv-185: Hemophilia severity categories
    Hemophilia severity categoriesMild: factor activity 5–40 IU/dL; Moderate: 1–5 IU/dL; Severe: <1 IU/dL
    Relevance to AlhemoAlhemo indicated for routine prophylaxis in hemophilia A or B; patient age and prior Hemlibra use criteria apply
    Guideline sourcesWorld Federation of Hemophilia and MASAC recommendations referenced
    inv-186: Alyglo definition
    Alyglo definitionAn IVIG product with an extra manufacturing step to reduce clotting factor XIa to undetectable levels
    Biosimilar/interchangeability noteAukelso is a biosimilar to Xgeva and provisionally interchangeable per FDA (contextual example in IVIG and biosimilar sections)
    Step therapy noteFor Part B determinations, must first try two preferred IVIG products (e.g., Gammagard Liquid, Gamunex-C, Privigen)
    inv-187: Polyneuropathy Disability (PND) score
    PND scorePolyneuropathy Disability (PND) score stages neuropathic impairment from 0 (no impairment) to IV (confined to wheelchair or bedridden); used to assess TTR-FAP severity
    ApplicationBaseline PND ≤ IIIb required for initial hATTR-PN coverage per policy
    DocumentationProvide baseline PND score in supporting medical records for authorization
    inv-188: Tc-PYP Grade 2 or 3 uptake definition
    Tc-PYP Grade 2/3 uptakeGrade 2 or 3 cardiac uptake on technetium-99m pyrophosphate (Tc‑PYP) scan confirms ATTR‑CM diagnosis in absence of monoclonal protein
    Diagnostic useIf diagnosis by radionuclide imaging, documentation of Grade 2 or 3 uptake is required for coverage
    Supporting testingAlso accept tissue biopsy or genetic testing when applicable; provide imaging reports in medical records
    inv-189: IVIG definition
    IVIG definitionIntravenous immunoglobulin (IVIG): human‑derived antibodies used to treat various autoimmune, infectious, and idiopathic diseases and primary immunodeficiency
    Clinical usesIncludes CIDP, myasthenia gravis exacerbations/crisis, ITP, and primary immunodeficiency among others
    Part B considerationsPart B vs Part D determination required; must try two preferred IVIG products for Part B requests
    inv-190: Biosimilar / Interchangeable definition
    Biosimilar / Interchangeable definitionA product highly similar to a reference biologic with no clinically meaningful differences; FDA may designate biosimilars as interchangeable
    ExampleAvtozma is a biosimilar to Actemra (tocilizumab); FDA determined it highly similar to reference product
    Policy implicationStep therapy often requires trial of specified biosimilars (e.g., Avsola or Renflexis) before reference biologic approval
    inv-191: Low testosterone diagnostic threshold definition
    Low testosterone diagnostic threshold definitionLow testosterone: total testosterone < 300 ng/dL on two separate morning measurements is a reasonable cut-off to support diagnosis
    Clinical requirementDiagnosis should combine low levels with signs/symptoms of testosterone deficiency; lab reference ranges may vary
    Guideline basisBased on AUA and Endocrine Society guidance referenced in the policy
    inv-192: Biosimilar (Avtozma) note
    Avtozma (biosimilar) noteAvtozma (tocilizumab-anoh) is a biosimilar to Actemra; FDA determined it highly similar to the reference product and is supported for use
    Step therapy implicationPolicy requires trial of Avsola OR Renflexis for most indications prior to tocilizumab biosimilar approval (except CRS, GCA, COVID-19 exceptions)
    Combination exclusionTocilizumab (and biosimilars) should not be used in combination with other biologics, Otezla, or JAK inhibitors due to infection risk
    inv-193: Cytokine release syndrome (CRS) definition
    Cytokine release syndrome (CRS) definitionA systemic inflammatory response often seen with CAR T‑cell therapy; tocilizumab in combination with glucocorticoids is standard therapy for moderate to severe cases
    Clinical managementTocilizumab plus glucocorticoids is foundational for CAR T‑cell associated CRS; other investigational strategies exist but are uncertain
    Policy impactCRS is an exception to some step therapy requirements for tocilizumab products per policy
    inv-194: Beizray / Beizray kit definition
    Beizray / Beizray kit definitionBeizray: a polysorbate‑80–free formulation of docetaxel; Beizray kit includes docetaxel injection plus human albumin solution for infusion
    Clinical noteDeveloped to mitigate hypersensitivity reactions associated with polysorbate‑80, though no demonstrated efficacy advantage over generic docetaxel
    Step therapyPolicy requires trial of generic docetaxel (Taxotere, J9171) before Beizray approval
    inv-195: Benlysta IV definition
    Benlysta IV definitionIntravenous belimumab for treatment of systemic lupus erythematosus (SLE) and lupus nephritis under specified coverage criteria
    Coverage constraintsNot to be used in combination with another biologic drug or Lupkynis
    Indication specificsDistinct criteria exist for SLE (SELENA‑SLEDAI ≥6 plus serologies) and lupus nephritis (biopsy-confirmed classes 3/4/5)
    inv-196: atypical hemolytic uremic syndrome (aHUS) term
    aHUS termAtypical hemolytic uremic syndrome (aHUS): syndrome of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury caused by complement dysregulation
    Diagnostic approachDiagnosed by labs and clinical exclusion of other causes (e.g., Shiga-toxin HUS, TTP)
    Policy relevanceIncluded in indication‑specific criteria for complement inhibitor therapies (e.g., Bkemv)
    inv-197: PNH definition
    PNH definitionParoxysmal nocturnal hemoglobinuria (PNH): hematopoietic stem cell disorder from a gene mutation causing GPI‑linked protein deficiency; diagnosed by flow cytometry
    Clinical featuresAssociated with intravascular hemolysis, thrombosis, and cytopenias; flow cytometry is gold standard diagnostic test
    Treatment contextComplement inhibitors (eculizumab class) are mainstay therapies; biosimilar interchangeable options noted in policy
    inv-198: aHUS expanded definition
    aHUS expanded definitionSyndrome of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury caused by complement dysregulation; diagnosed by labs and exclusion of other causes
    Clinical markersSigns include increased LDH, increased creatinine, and decreased platelet count consistent with TMA
    Policy implicationReauthorization requires demonstration of improvement in TMA markers for ongoing coverage
    inv-199: PNH expanded definition
    PNH expanded definitionHematopoietic stem cell disorder causing GPI‑linked protein deficiency leading to hemolysis and thrombotic risk; flow cytometry confirms diagnosis
    Treatment considerationsComplement C5 inhibitors improve hemolysis and symptoms; documentation of hemolysis-associated symptoms and flow cytometry required for coverage
    Reauthorization criteriaDemonstration of hemoglobin increase and reduced transfusion dependence supports ongoing coverage
    inv-200: Transfusion dependent beta thalassemia definition
    Transfusion dependent beta thalassemia definitionHistory of at least 100 mL/kg/year OR ≥10 units/year of packed RBCs in the previous 2 years
    Documentation requirementProvide transfusion records covering the prior 2 years with PA request
    Casgevy-specific noteAlso requires no known/available HLA-matched donor and provider attestation of HSCT eligibility in absence of donor
    inv-201: Severe SCD for Casgevy eligibility
    Severe SCD for Casgevy eligibilityDocumented βS/βS, βS/β0, or βS/β+ genotype AND history of ≥2 severe vaso-occlusive events per year in the previous 2 years
    Additional requirementsCurrent weight, adequate organ function, HSCT eligibility, and prior hydroxyurea failure or intolerance are required
    Authorization limitsAuthorization duration 6 months; Casgevy limited to one lifetime dose
    inv-202: Severe eosinophilic asthma definition
    Severe eosinophilic asthma definitionAsthma phenotype with elevated blood eosinophils (≥150 cells/µL at baseline OR ≥300 cells/µL in prior 12 months) and poor control/exacerbations despite optimized inhaled therapy
    Therapy prerequisitesMust have tried and failed high‑dose ICS/LABA plus another controller in past 6 months before biologic initiation
    DocumentationEosinophil counts and prior controller therapy trials must be provided with PA request
    inv-203: Cosentyx definition
    Cosentyx definitionSecukinumab (Cosentyx) is an IL‑17 receptor A antagonist indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis
    Coverage contextCosentyx IV (policy) requires prior trial of Avsola, Renflexis OR Simponi Aria and prescriber specialist involvement
    DurationCoverage duration: 2 years per policy
    inv-204: Docivyx definition
    Docivyx definitionDocivyx: polysorbate‑80–free formulation of docetaxel indicated for several solid tumors; developed to mitigate hypersensitivity reactions associated with polysorbate‑80
    Step therapyMust first try generic docetaxel (Taxotere, J9171) before Docivyx approval
    Coverage durationCoverage duration: 1 year per policy
    inv-205: Durysta definition
    Durysta definitionBimatoprost intracameral biodegradable implant indicated to lower intraocular pressure in open‑angle glaucoma or ocular hypertension
    Prior therapy requirementMust try TWO topical prostaglandin analogs (latanoprost, bimatoprost, travoprost) before Durysta per policy
    Coverage/step therapyStep therapy applies; coverage and duration per FDA labeling and policy
    inv-206: anti-AAVrh74 titer definition
    anti-AAVrh74 titer definitionSerologic total binding antibody titer against AAVrh74; coverage for Elevidys requires anti‑AAVrh74 total binding antibody titer < 1:400
    Clinical implicationPatients with titers ≥ 1:400 are ineligible for Elevidys per prescribing information and policy
    DocumentationProvide antibody titer result with PA request; also require genetic confirmation of DMD mutation not involving exon 8 or 9
    inv-207: Contraindicated DMD deletions definition
    Contraindicated DMD deletionsAny deletion in exon 8 and/or exon 9 of the DMD gene is a contraindication to Elevidys
    Coverage prerequisiteProvide genetic testing confirming DMD mutation that does not include exon 8 or 9 deletions
    Additional requirementAnti‑AAVrh74 titer must be <1:400 per prescribing information
    inv-208: Enjaymo definition
    Enjaymo definitionEnjaymo (sutimlimab‑jome) is a classical complement inhibitor indicated for treatment of hemolysis in adults with cold agglutinin disease (CAD); dosing determined by weight with initial weekly infusions then every two weeks
    Dosing example6,500 mg for 39–<75 kg or 7,500 mg for ≥75 kg IV weekly for two weeks then every two weeks thereafter
    Initiation requirementsDocumented CAD diagnosis and at least one blood transfusion within prior 6 months required for initiation per policy
    inv-209: Entyvio definition
    Entyvio definitionEntyvio (vedolizumab) is an integrin receptor antagonist indicated for Ulcerative Colitis and Crohn's Disease
    Step therapyMust first try Avsola OR Renflexis prior to Entyvio approval per Part B step therapy requirement
    Prescriber requirementPrescriber should be a specialist or have consulted one for the treated condition